Select Medical (SEM) Q4 2025 earnings review
Top-Line Growth Overshadowed by Outpatient Margin Collapse
Select Medical reported a mixed Q4. While revenue grew 6.4% to $1.4B, driven by a 15% surge in the Rehabilitation Hospital segment, profitability quality deteriorated significantly. Adjusted EBITDA fell nearly 10% YoY to $104.7M, primarily due to a shocking collapse in Outpatient Rehabilitation margins (down to 3.4% from 8.3%). Net income rose on a reported basis, but largely due to the absence of prior-year one-time charges related to the Concentra spin-off. The quarter is heavily contextualized by the pending 'Take Private' proposal from the Executive Chairman at $16.00-$16.20/share.
🐂 Bull Case
The Rehabilitation Hospital segment is growing rapidly, with revenue up 15.2% and Adjusted EBITDA up 11.1%. Admissions grew nearly 10% YoY, proving the joint-venture strategy is capturing volume.
Despite regulatory headwinds feared throughout the year, the Critical Illness (LTAC) segment held firm. Revenue grew 4.9% and margins remained stable at 10.5% (flat YoY), contributing steady EBITDA.
🐻 Bear Case
The Outpatient Rehab segment suffered a catastrophic quarter. Despite 1.6% revenue growth, Adjusted EBITDA collapsed 58% YoY ($11.2M vs $26.6M). Margins evaporated to 3.4%, signaling severe operating leverage issues or cost mismanagement.
Q4 Operating Cash Flow nearly halved to $64.3M from $125.4M in the prior year. For the full year, OCF is down 33% ($346M vs $517M), raising concerns about working capital efficiency post-spin.
⚖️ Verdict: 🔴
Bearish. While the top-line growth in Inpatient Rehab is excellent, the sudden 58% drop in Outpatient EBITDA and significant cash flow contraction are alarming. The 'Take Private' offer creates a floor, but operational fundamentals weakened in Q4.
Key Themes
Outpatient Rehabilitation Margin Collapse
A massive red flag. The Outpatient segment's Adjusted EBITDA margin crashed to 3.4% in Q4 from 8.3% a year ago and 7.4% in Q3. Revenue per visit dropped 3.9% to $98, likely driven by reimbursement pressure or mix shift, while costs failed to adjust. This single segment dragged consolidated EBITDA into negative growth territory.
Inpatient Rehabilitation (IRF) Growth
The clear standout performer. Revenue surged 15.2% and EBITDA 11.1%. Admissions were up 9.6%. This segment now generates nearly 6x the EBITDA of the Outpatient segment ($69M vs $11M) and is the primary thesis for the company's standalone value.
Take Private Proposal
On November 24, 2025, Executive Chairman Robert Ortenzio proposed to acquire all outstanding shares for $16.00-$16.20 cash. A Special Committee has been formed. This puts a temporary floor on the stock but also caps upside unless the committee negotiates a higher price or a competing bid emerges.
Operating Cash Flow Compression
Full-year Operating Cash Flow fell 33% to $346M. Q4 specifically saw a drop to $64M from $125M YoY. Accounts Receivable rose to $864M from $821M YoY despite the removal of Concentra, indicating potential collection slowing or billing delays.
Debt & Leverage
Following the Concentra spin and debt paydown, Interest Expense stabilized ($28.9M vs $28.6M YoY). Long-term debt net of current portion increased slightly to $1.80B from $1.69B YoY. The company is actively deleveraging relative to the pre-spin structure, but debt remains a key capital allocation focus.
Other KPIs
Stable growth of 4.9%. This segment is often viewed as a drag due to regulatory risks, but it delivered consistent performance in Q4 with EBITDA up 5.3%.
Down 3.4% from $510.4M in FY24. The decline reflects the loss of Concentra (discontinued ops) and the Q4 weakness in Outpatient Rehab.
Reversing. Profitable vs a loss of ($0.19) in 24Q4. However, the prior year was weighed down by $45.9M in accelerated stock comp and debt retirement losses. Adjusted EPS fell 11% ($0.16 vs $0.18), showing true earnings power declined.
Guidance
Stable. The midpoint ($5.7B) implies ~4.5% YoY growth vs FY25's $5.45B. This suggests management expects the volume trends in IRF and LTAC to continue.
Accelerating. The midpoint ($530M) implies ~7.5% growth vs FY25 ($493M). This forecast requires a significant turnaround in the Outpatient segment or continued double-digit compounding in IRF to offset Q4's weakness.
Accelerating. Implies growth of 5% to 14% over FY25's $1.16. Driven by EBITDA expansion and potentially lower interest expenses or share count stability.
Key Questions
Outpatient Margin Collapse Drivers
Outpatient EBITDA margins fell from 8.3% to 3.4% in a single quarter despite revenue growth. Was this driven by a specific payer mix shift, labor cost spike, or write-offs?
Cash Flow Conversion
Operating Cash Flow dropped 33% YoY in FY25. With the 'Take Private' offer on the table, what is the normalized free cash flow conversion expectation for the standalone business in 2026?
Special Committee Timeline
With the buyout proposal received in November 2025, is there an expected timeline for the Special Committee's recommendation, and are there competing bids being solicited?